Subcutaneous · PYY / Y2 agonist
NNC0165-1875
2 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
2
Active
0
Recruiting
0
Completed
2
Sites
26
Countries
1
Endpoints
35
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
1
Phase 2
1
Trials by status
Completed
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Cardiometabolic biomarkers
12
Safety / tolerability / PK
11
Weight & body composition
6
Glycemic / diabetes
6
Most-measured metrics
Top 20 metrics across this asset's endpoints
Treatment-emergent AEs (any)Safety/PK
5
Body weight, % changeWeight
2
Body weight, absolute change (kg)Weight
2
HbA1c, changeGlycemic
2
Fasting glucose, changeGlycemic
2
Waist circumference, changeWeight
2
Total cholesterol, changeBiomarker
2
HDL-C, changeBiomarker
2
LDL-C, changeBiomarker
2
VLDL, changeBiomarker
2
Triglycerides, changeBiomarker
2
Free fatty acids, changeBiomarker
2
Serious AEs (any)Safety/PK
2
AUC₀–∞Safety/PK
2
CmaxSafety/PK
2
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
2 of 2
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT04969939A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity | NNC0165-1875, Semaglutide Obesity / overweight | BMI 30-45 | Ph 2 | Completed | 25 | Dec 2022 | — | results |
| NCT03707990A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese | NNC0165-1875, Semaglutide Obesity / overweight | BMI 25-34.9 | Ph 1 | Completed | 1 | Aug 2019 | — |